CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
CONMED CorporationNYSE: CNMD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $18.61M fell 2.0% year over year, ahead of the -115.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -23.2% a year.
Context
- Accounts receivables amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -2.0% holds above the trailing-twelve-month pace of -115.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.36M) USD
- Year-over-year change
- -45.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.36M) | -45.8% |
| FY2024 | 2024-12-31 | (1.62M) | +96.6% |
| FY2023 | 2023-12-31 | (47.07M) | -804.6% |
| FY2022 | 2022-12-31 | (5.2M) | +43.2% |
| FY2021 | 2021-12-31 | (9.16M) | — |
Accounts Receivables vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 accounts receivables of $2.74M is the 9th largest of the 11 companies compared; the peer median is $8.14M.
- Its year-over-year change of -115.0% is the lowest of 11, against a peer median of +77.8%.
- Accounts receivables amounts to 0.2% of revenue for CNMD, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.5M | -6.9% | — | 4.4% | |
| LTM Jun 2026 | $25.79M | +400.5% | — | 4.1% | |
| LTM Apr 2026 | $25.35M | +2637.1% | — | 0.9% | |
| LTM Mar 2026 | $18.61M | +248.4% | +2.2% | 5.0% | |
| LTM Mar 2026 | $14.56M | +1796.8% | +131.9% | 30.0% | |
| LTM Jan 2026 | $8.99M | +37.6% | — | 10.7% | |
| LTM Sep 2026 | $7.29M | -28.1% | -2.4% | 2.8% | |
| LTM Sep 2026 | $4.42M | +118.0% | -49.6% | 0.7% | |
| LTM Mar 2026 | $2.74M | -115.0% | -23.2% | 0.2% | |
| LTM Mar 2026 | $1.37M | -94.7% | -18.2% | 2.1% | |
| LTM Aug 2026 | $407K | -101.7% | — | 0.0% | |
| Peer median (excluding CNMD) | $8.14M | +77.8% | -2.4% | 3.4% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Depreciation & Amortization | 70.74M | 69.52M | 51.4M | 51.31M | 74.28M |
| Deferred Income Tax | 3.01M | (6.04M) | 700K | 12.2M | 3.52M |
| Stock-Based Compensation | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M |
| Change in Working Capital | (55.7M) | (90.7M) | (39.58M) | (39.72M) | (11.45M) |
| Accounts Receivables | (9.16M) | (5.2M) | (47.07M) | (1.62M) | (2.36M) |
| Inventory | (37.81M) | (78.56M) | 14.07M | (31.63M) | (6.73M) |
| Accounts Payables | 4.89M | 13.3M | 14.85M | 14.71M | (9.75M) |
| Other Working Capital | (13.62M) | (20.23M) | (21.43M) | (21.19M) | 7.39M |
| Other Non-Cash Items | 14.84M | 119.44M | 24.11M | (14.8M) | 28.96M |
| Operating Cash Flow | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M |
| Capital Expenditures | (14.87M) | (21.79M) | (19.03M) | (13.08M) | (19.81M) |
| Acquisitions (Net) | 0 | (227.74M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | (1.15M) |
| Investing Cash Flow | (14.87M) | (249.53M) | (20.03M) | (13.08M) | (20.96M) |
| Debt Repayment | (81.24M) | 362.02M | (88M) | (72M) | (74.59M) |
| Common Stock Issued | 0 | 72M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (72M) | 0 | 0 | 0 |
| Dividends Paid | (23.26M) | (23.96M) | (24.5M) | (24.65M) | (24.75M) |
| Other Financing Activities | 2.95M | (113.06M) | 2.07M | (54.35M) | (36.49M) |
| Financing Cash Flow | (101.55M) | 225M | (110.43M) | (151M) | (135.82M) |
| Effect of Forex Changes | (1.87M) | (741K) | 470K | (2.72M) | 2.45M |
| Net Change in Cash | (6.51M) | 8.1M | (4.65M) | 163K | 16.36M |
| Free Cash Flow | 96.9M | 11.58M | 106.32M | 153.88M | 150.88M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.